Articles

It is inevitable that patients with cancer will experience some side effects associated with treatment. Recommendations for managing and minimizing these complications are critical to patients’ well-being and can impact overall clinical outcomes.

As an oncology pharmacist in an ambulatory cancer clinic, in the course of a typical week, it is not unusual for me to counsel 25 to 30 new patients on chemotherapy regimens that they are about to receive (paying particular attention to adverse events [AEs]), and to be directly involved in the monitoring and management of countless other patients who present with side effects associated with their treatments.

In its eighth year, The Oncology Pharmacist (TOP) will continue to provide oncology pharmacists and their colleagues with the latest research findings and results of large clinical trials, interviews with thought leaders, as well as content for pharmacy students and residents, and articles on practice management.

St. Joseph’s/Candler Health System was established through a joint operating agreement between 2 religious institutions—St. Joseph’s, a Catholic hospital, and Candler, a Methodist hospital. It is the only faith-based healthcare system in southeast Georgia.

Because of the complexity of biosimilar regulations, a pharmaceutical and therapeutics committee—which includes pharmacists and physicians—is recommended to determine appropriate biosimilar use...

The expanding availability of oral drugs for the treatment of a number of tumor types has increased their use as chemotherapy.

The annual meetings of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS) took place in December 2014, attracting US and international oncologists interested in the latest research on basic science and clinical medicine. These are a selection of highlights from these meetings.

Two programmed cell death receptor-1 (PD-1) inhibitors—the investigational drug nivo­lumab and the recently approved pem­bro­lizumab (Keytruda)—produced dramatic responses in patients with Hodg­kin lymphoma in phase 1 clinical trials.

The Third Annual World Cutaneous Malignancies Congress (WCMC) took place in San Francisco, CA, on October 30-31, 2014.